Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis

Antitumor imidazoacridinone C-1311 is a DNA-reactive topoisomerase II and FLT3 receptor tyrosine kinase inhibitor. Here, we demonstrate the mechanism of C-1311 inhibitory action on novel targets: hypoxia-inducible factor-1α (HIF-1α), vascular-endothelial growth factor (VEGF), and angiogenesis. In a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer biology & therapy 2011-10, Vol.12 (7), p.586-597
Hauptverfasser:	Paradziej-Łukowicz, Jolanta, Skwarska, Anna, Peszyńska-Sularz, Grażyna, Brillowska-Dąbrowska, Anna, Konopa, Jerzy
Format:	Artikel
Sprache:	eng
Schlagworte:	Aminoacridines - pharmacology Angiogenesis Inhibitors - pharmacology Animals Antineoplastic Agents - pharmacology Binding Binding Sites Biology Bioscience Calcium Cancer Cell Cell Line, Tumor Cell-Free System Colonic Neoplasms - drug therapy Colonic Neoplasms - metabolism Colonic Neoplasms - pathology Cycle Dose-Response Relationship, Drug Humans Hypoxia-Inducible Factor 1, alpha Subunit - antagonists & inhibitors Hypoxia-Inducible Factor 1, alpha Subunit - genetics Landes Melanoma - drug therapy Melanoma - metabolism Melanoma - pathology Mice Mice, Inbred C57BL Neovascularization, Pathologic - drug therapy Organogenesis Proteins Response Elements Tumor Suppressor Protein p53 - genetics Vascular Endothelial Growth Factor A - antagonists & inhibitors Vascular Endothelial Growth Factor A - genetics Vascular Endothelial Growth Factor A - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!